1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd.

TTPEX:6733
23.55
TWD
-0.40
(-1.67%)
3.25BMarket Cap
Nov 05Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.02
0.02
0.09
0.3
0.91
1.36
1.8
- -
Basic EPS, GAAP
- -
-3.13
-2.72
-1.97
-1.64
-1.36
-1.78
-1.3
-0.94
-0.69
- -
Free Cash Flow per Basic Share
- -
-3.41
-2.41
-2.17
-1.32
-1.35
-1.81
-1.36
-0.81
-0.53
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.19
4.29
7.59
7.07
7.54
8.47
6.8
7.62
6.56
5.95
7.95
Tangible Book Value per Share
1.83
2.91
6.37
5.64
6.44
5.81
4.59
6.26
5.51
5.22
7.42
Basic Weighted Avg Shares
83
44
62
83
89
102
103
121
123
123
129
Sales/Revenue/Turnover
- -
- -
- -
1
1
9
31
110
168
222
- -
Operating Margin (%)
- -
- -
- -
-11,438.26
-9,591.89
-1,772.67
-697.11
-160.63
-72.93
-49.34
- -
Depreciation Expense
- -
9
17
18
19
28
53
55
51
50
- -
Net Income, GAAP
- -
-138
-167
-163
-146
-138
-184
-156
-116
-85
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-11,150.1
-10,451.83
-1,494.07
-586.58
-142.23
-69.47
-38.05
- -
Working Capital
76
153
444
380
528
709
510
755
684
600
940
LT Debt
- -
- -
- -
- -
- -
- -
12
9
6
3
1
Total Equity
182
358
632
589
705
943
731
957
847
758
1,080
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-51.27
-33.84
-26.67
-22.51
-17.4
-23.2
-19.02
-13.25
-10.85
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
125
134
Market Capitalization
4,775
4,078
3,250

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
636
982
971
Cash, Cash Equivalents & STI
518
862
850
Accounts Receivable, Net
59
59
59
Inventories
21
28
28
Total Current Liabilities
36
29
30
Payables & Accruals
- -
- -
- -
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.05%
-10.5%
Free Cash Flow
- -
-6.5%
-34.19%
Net Income, GAAP
- -
-7.96%
-27.36%
Sales/Revenue/Turnover
- -
227.86%
32.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36
37
44
51
168
2025
47
53
- -
60
222
2026
55
59
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.28
-0.25
-0.32
-0.94
2025
-0.27
-0.19
- -
-0.17
-0.69
2026
-0.13
-0.18
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Te-Li Chen
Full Time Employees
34
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No.3-2, Park Street Taipei TP Taiwan 115
IPO Date
Jan 28, 2021
Website
biogend.com.tw
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
BioGend Therapeutics Co., Ltd. (6733.TWO) researches, develops, and commercializes orthopedic medical devices and biologics focused on bone and cartilage repair and regeneration; its core products include RevoCart, a one-step autologous cartilage repair system approved in Taiwan for treating knee chondral and osteochondral defects in patients with mild to moderate osteoarthritis, as validated by phase III clinical trials and two-year follow-up studies demonstrating restored patient activity; Osteo-Inductive Factor (OIF, a recombinant human BMP-2 or rhBMP-2 product), an osteoinductive bone graft substitute applicable to long bones, spine, and dental regeneration, supported by over ten years of preclinical data and ongoing multinational clinical trials including a pilot for open fracture management and spinal fusion; and developmental candidates such as BiG-001 and BiG-006 osteoinductive bone graft substitutes, alongside BiG-009 autologous cartilage repair system. The company, founded in 2016 and headquartered at No. 3-2, Park Street, 4th Floor, Nangang District, Taipei, 115, Taiwan, operates primarily in the biotechnology and healthcare sectors targeting orthopedic surgeons, hospitals, and patients with musculoskeletal conditions; it serves markets in Taiwan with expansion via out-licensing of RevoCart to partners in China and ASEAN countries, and OIF to partners in Japan and China. Recent developments include sustained clinical progress for OIF with interim analysis results from the BiG-001 trial showing high success rates across low, medium, and high doses within 30 weeks post-operation; completion of pivotal enrollment for cartilage repair technologies leading to regulatory approvals; and steady revenue growth in medical devices and CDMO services, with Q2 2025 earnings reflecting operational stability amid investments in orthobiologic advancements.